1

Samsung Group has established a new 200-billion-won investment fund dedicated to discovering innovative biotechnology companies.

Samsung Mulsaun, Samsung Biologics, and Samsung Bioepis jointly pooled resources to complete the formation of the Samsung Life Science Fund III (SVIC-80), Samsung Biologics announced on June 1. The fund centers on aggressively scouting global enterprises armed with breakthrough biotech capabilities and expanding strategic partnerships.

A breakdown of the investment structure shows that Samsung C&T and Samsung Biologics contributed the largest shares, committing 79.2 billion won (39.6 percent) each. Samsung Bioepis chipped in 39.6 billion won (19.8 percent), while Samsung Venture Investment, which is tasked with managing the fund, injected 2 billion won (1.0 percent). With this third vehicle following the 170-billion-won Fund I in 2019 and the subsequent 72-billion-won Fund II, Samsung's cumulative investment pool earmarked for the life sciences sector has swollen to 442 billion won.

Leveraging this third fund as a springboard, Samsung Group plans to significantly accelerate the tempo of its investments in next-generation biotechnology. The blueprint extends beyond reaping simple financial returns; it aims to continuously expand Samsung's global biotechnology network through practical business collaboration with its portfolio companies.

The Samsung Life Science Fund currently maintains active investments in a slate of global biotech firms and venture capital entities, including AimedBio, Flagship Pioneering, Latus Bio, Generate Biomedicines, C2N Diagnostics, Arbor Biotechnologies, Frontline Biome, and Cartography Biosciences. Industry observers anticipate that the closing of Fund III will pave the way for Samsung Group to further diversify its portfolio across the bio and healthcare sectors.

                                                                                                            Choi Jung-ah